8-K: Cyclacel Pharmaceuticals Implements 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing

Cyclacel Pharmaceuticals, Inc. announced a 1-for-15 reverse stock split, effective July 7, 2025, primarily to meet Nasdaq Capital Market's bid price requirements.

Summary

• Cyclacel Pharmaceuticals, Inc. has implemented a one-for-fifteen reverse stock split of its common stock.
• The reverse stock split became effective on July 7, 2025, with trading on a split-adjusted basis commencing at market open on the same day.
• The primary purpose of the reverse stock split is to meet the share bid price requirements of The Nasdaq Capital Market.
• Every fifteen shares of common stock issued and outstanding automatically combined into one share of common stock.
• No fractional shares will be issued; instead, fractional shares will be rounded up to the nearest whole number if one-half or more, and rounded down if less than one-half.
• The par value per share of common stock remains unchanged at $0.001.
• The company's common stock trading symbol will remain CYCC, and a new CUSIP number (23254L876) has been assigned.
• Pre-reverse stock split, there were 23,759,475 shares of common stock issued and outstanding, which will be reduced to 1,583,965 shares post-split.
• All outstanding options, warrants, and other convertible securities will be adjusted in accordance with their governing terms.

Sentiment

Score: 4

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for continued market access. However, the underlying reason for needing a reverse split (low share price) indicates past or ongoing challenges. The document itself is factual about the implementation, not overtly positive or negative in tone beyond the necessity of the action.

Positives

• The reverse stock split is intended to enable Cyclacel Pharmaceuticals to meet The Nasdaq Capital Market's minimum bid price requirements, thereby maintaining its listing.

Negatives

• A reverse stock split often indicates a low share price, which can be perceived negatively by investors.
• While the percentage interest remains the same, the reduction in the number of outstanding shares might lead to reduced liquidity.

Risks

• The company's ability to regain and maintain compliance with Nasdaq's continued listing requirements is not assured.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially, including market conditions, product candidate efficacy and/or safety in larger-scale or later clinical trials, difficulties in trial enrollment, failure to obtain approval to market product candidates, risks associated with reliance on outside financing to meet capital requirements, and risks associated with reliance on collaborative partners for further clinical trials, development, and commercialization of product candidates.

Future Outlook

The company's future plans and prospects, anticipated cash runway, and planned timing of data results and continued development of plogosertib are forward-looking statements that involve risks and uncertainties. The company's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.

Management Comments

• Cyclacel Pharmaceuticals ANNOUNCES STOCK SPLIT

Industry Context

Reverse stock splits are common for companies, particularly in the biotechnology or pharmaceutical sector, that have experienced significant share price declines and need to meet exchange listing requirements. This action is a defensive measure to maintain market visibility and investor access, rather than an indicator of new strategic growth or product development.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the document for direct comparison. The action of a reverse stock split to meet listing requirements is a standard practice across various industries for companies facing similar challenges.

Corporate Governance

Stakeholder Impact

• Shareholders: Their percentage ownership remains unchanged, but the number of shares they hold will decrease by a factor of fifteen. Fractional shares are rounded, which may slightly alter individual holdings. The goal is to maintain Nasdaq listing, which benefits shareholders by ensuring continued liquidity and market access.

Next Steps

• Trading of common stock on a split-adjusted basis will begin on July 7, 2025.
• Options, warrants, and other convertible securities will be adjusted in accordance with their terms.
• Continued development of plogosertib.

Key Dates

Recommendation

Keywords

Cyclacel Pharmaceuticals, CYCC, reverse stock split, Nasdaq Capital Market, stock split, biopharmaceutical, cancer medicines, oncology, hematology, plogosertib, PLK1 inhibitor, corporate governance, stock exchange listing